In this issue, Pelosi and colleagues present the results of a gene alteration analysis of a large series of pulmonary neuroendocrine carcinomas. This study provides molecular support for the concept that carcinoid tumors can transform into highgrade neuroendocrine carcinomas through the acquisition of additional molecular alterations. This concept challenges the current and widely held belief that carcinoid tumors are different histogenetic entities from the high-grade neuroendocrine carcinomas thereby denying the existence of any transitional forms.
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Neuroendocrine carcinomas of the lung are a group of tumors that originate from the diffuse neuroendocrine system of the bronchopulmonary tree. These neoplasms have been the subject of intense debate for more than a century due to divergent opinions on the concept and classification of these tumors and their relation to biologic behavior. Hence, the literature to date contains numerous proposals for histopathologic classification. The current World Health Organization (WHO) Classification of Lung Tumors [1] separates pulmonary neuroendocrine carcinomas into four major categories based on a combination of tumor morphology, mitotic activity, and presence of necrosis: carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma, and small cell carcinoma. Clinically, these four categories translate into a threetiered grading system with carcinoid tumor representing the low grade, atypical carcinoid tumor the intermediate grade, and large cell neuroendocrine carcinoma and small cell carcinoma the high-grade end of the malignant spectrum [1] . This prognostic categorization is reflected in the clinical management of the patients: while those with carcinoid tumor are treated with surgery alone, individuals with atypical carcinoid often require additional systemic therapy and management of patients with high-grade tumors usually includes a combination of surgery and systemic therapy or systemic therapy alone [2] . Although the WHO classification of pulmonary neuroendocrine carcinomas is currently the most widely used system, this schema is not without controversy, largely due to the rigid diagnostic criteria applied to each category and problems with reproducibility and prognostic efficacy [3] . Additionally, current concepts of the pathogenesis of these tumors support the idea that carcinoid tumors are independent neoplasms that should not be considered progenitor lesions that can transform into high-grade tumors. This view is largely based on studies investigating the genomic landscape of these tumors, the results of which have revealed different mutational patterns in the carcinoid group compared to the high-grade tumors [4] [5] [6] .
Contrary to that, the current study by Pelosi et al. provides evidence of widely shared genetic alterations across all subtypes of pulmonary neuroendocrine carcinomas supporting the concept that carcinoid tumors can progress towards highgrade lesions as a result of accumulation of genetic damage during tumor progression. Their results confirm that Bsecondary^high-grade neuroendocrine carcinomas can indeed arise from lower-grade progenitor lesions supporting similar observations in other organ systems. This finding elegantly underscores a number of important prior observations that would support this notion. For instance, tumors that by current diagnostic criteria are composed of more than one pattern or that show transitional forms within the same tumor mass have long been recognized in the literature [7, 8] . In addition, neoplasms that show low-grade morphologic features but have mitotic counts exceeding the specified cutoff have not only been described in other organ systems but are increasingly also observed in the lung [9] . In a similar manner, cases of pulmonary carcinoid tumors have been documented that show higher proliferation rates in their metastatic sites than in the primary tumor [10] . Furthermore, any practicing pathologist is only too aware of the diagnostic intricacies when it comes to distinguishing atypical carcinoid from large cell neuroendocrine carcinoma or separating large cell neuroendocrine carcinoma from small cell carcinoma in certain cases. All these examples seem to provide the morphologic basis in support of a concept of tumor transformation among this group of neoplasms.
The results of the analysis by Pelosi et al. also expose two other important issues. First, evidence of the ability of carcinoid tumors to transform into high-grade tumors raises concerns about the current terminology of pulmonary neuroendocrine carcinomas as stipulated by the WHO classification [1] . Use of outdated terminology such as Bcarcinoid tumor^and Batypical carcinoid tumor^to describe lesions that have at least low or intermediate grade malignant potential should best be avoided and replaced by a nomenclature highlighting their malignant nature, i.e., Blow grade neuroendocrine carcinoma^and Bintermediate grade neuroendocrine carcinoma^, respectively. Failure to do so will not only misguide clinicians but also give patients a false sense of security. Second, the current classification and grading of pulmonary neuroendocrine carcinomas according to the WHO schema (1) is suboptimal as it fails to appropriately classify a significant number of tumors that may not unequivocally fall into the existing categories. Misclassification of such tumors may result in adverse consequences for patient management and prognosis. Hence, a novel and more flexible approach, perhaps with greater emphasis on proliferative activity rather than cytologic detail to distinguish between tumor subtypes should be explored for use in future classifications.
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